About Deep Track Capital
Deep Track Capital is a venture capital firm founded in 2020. It is primarily based out of Greenwich, United States. As of Oct 2026, Deep Track Capital is an active investor, having invested in 61 companies, with 13 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Post IPO round of Bolt Biotherapeutics Overall, Deep Track Capital portfolio has seen 31 IPOs and 11 acquisitions including key companies like GRAIL, X4 Pharmaceuticals and Attovia. A lot of funds co-invest with Deep Track Capital, with names like RA Capital Management sharing a substantial percentage of its portfolio. Deep Track Capital has team of 15 people including 7 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Post IPO & 4 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Deep Track Capital's List of Top Investments
Deep Track Capital has a portfolio of 61 companies. Their most notable investments are in Mariana Oncology and MBX Biosciences.Their portfolio spans across United States, United Kingdom, Canada and 3 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 3 other sectors, across stages such as Series B, Post IPO and 4 more. Here is the list of top investments by Deep Track Capital:
1. GRAIL
Developer of a screening platform for circulating tumor DNA to detect cancer. The company is developing a test called "Galleri" a pan-cancer screening test by measuring circulating nucleic acids in the blood. Its proprietary platform uses the ultra-deep sequencing technique to measure levels of circulating tumor DNA in the patient's blood.
Key facts about GRAIL
- Founded Year: 2016
- Location: Menlo Park (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $2B
- Employee Count: 1,141 as on Sep 30, 2026
- Investors: Foresite Capital, Gershon Capital and 52 Others
- Latest Funding Round: Post IPO, Jun 25, 2026, $*****
- Highlight: Public
Developer of small molecule drugs for the treatment of cancer. The company's therapeutics are designed to improve immune cell trafficking and increase the ability for T-cells to track and destroy cancer cells. The company's small molecule drug candidate includes X4P-001 that inhibits C-X-C receptor type 4, a receptor overexpressed in many cancers. It is also used for the treatment of rare genetic disorders. The company's second program, X4P-002, for the treatment of brain cancers, including glioblastoma multiforme.
Key facts about X4 Pharmaceuticals
- Founded Year: 2014
- Location: Boston (United States)
- Annual Revenue: $1M - $10M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $58.2M
- Employee Count: 77 as on Sep 30, 2026
- Investors: Bain Capital Life Sciences, BVF Partners and 22 Others
- Latest Funding Round: Post IPO, Aug 13, 2025, $*****
- Highlight: Public
3. Attovia
Developer of antibody-based therapeutics for immune-mediated diseases and oncology. The company leverages ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. It develops a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology.
Key facts about Attovia
- Founded Year: 2023
- Location: Fremont (United States)
- Stage: Public
- Total Funding till date: $255M
- Employee Count: 54 as on Sep 30, 2026
- Investors: Marshall Wace, Frazier Life Sciences and 13 Others
- Latest Funding Round: Series C, Apr 15, 2025, $*****
- Highlight: Public
Developer of therapeutics for the treatment of autoimmune diseases and cancer. The company's iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development and manufacturing capabilities to generate allogeneic, iPSC-derived therapies for autoimmune diseases and cancer.
Key facts about Century Therapeutics
- Founded Year: 2018
- Location: Philadelphia (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $410M
- Employee Count: 120 as on Sep 30, 2026
- Investors: Bain Capital Life Sciences, Venrock and 22 Others
- Latest Funding Round: Post IPO, Jan 08, 2026, $*****
- Highlight: Public
Imbria Pharmaceuticals provides therapeutics solution by translation the cellular metabolism. It is involved in providing transformative medicine, by altering the cellular metabolism and mitochondrial function.
Key facts about Imbria Pharmaceuticals
- Founded Year: 2014
- Location: Boston (United States)
- Stage: Series B
- Total Funding till date: $157M
- Employee Count: 16 as on Sep 30, 2026
- Investors: RA Capital Management, Deep Track Capital and 6 Others
- Latest Funding Round: Series B, Nov 17, 2025, $*****
- Highlight: Editors' Pick
Deep Track Capital's Year-on-Year Investment Trends
Deep Track Capital has invested in 61 companies over the last 5 years, with an average of 11 new investments annually in the last 5 years. In 2025, it made 10 investments, while as of Oct 2026, it has made 16 investments in this year. Its most recent first time investment was in Bolt Biotherapeutics and most recent follow-on round was in Obsidian Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 13 | 3 | 16 |
2025 | 5 | 5 | 10 |
2024 | 15 | 5 | 20 |
2023 | 9 | 2 | 11 |
2022 | 11 | 0 | 11 |
2021 | 8 | 0 | 8 |
Deep Track Capital's Investments by Stage
Deep Track Capital has made 24 investments in Series B stage with an average round size of $131M, 23 investments in Post IPO stage with an average round size of $160M and 6 investments in Series C stage with an average round size of $88.1M.Stage of entry | No. of Investments |
|---|---|
Series B | 24 |
Post IPO | 23 |
Series C | 6 |
Series A | 4 |
Series D | 3 |
Others | 1 |
Note: We have considered here, only first round of investments
Deep Track Capital's Investments by Sector
Deep Track Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Healthcare, HealthTech and Consumer. Notably, it has invested in 56 Tech companies, 53 Enterprise (B2B) companies, 3 Software companies and at least 2 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 57 |
High Tech | 10 |
Healthcare | 4 |
HealthTech | 3 |
Consumer | 2 |
Others | 4 |
Note: We have considered here, only first round of investments
Deep Track Capital's Investments by Geography
Deep Track Capital has made most investments in United States (48), followed by United Kingdom where it has made 5 investments.Country | No. of Investments |
|---|---|
United States | 48 |
United Kingdom | 5 |
Canada | 3 |
France | 3 |
Denmark | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Deep Track Capital's recent investments
Deep Track Capital has made 16 investments in 2026 so far. Bolt Biotherapeutics and Estuary Bio are the latest among them.Here are the most recent investments by Deep Track Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Oct 23, 2026 | United States | Post IPO | 8944 | [+10] | |
Oct 16, 2026 | United States | Series A | 1753 | ||
Aug 10, 2026 | United States | Series B | 3515 | [+8] | |
Aug 05, 2026 | United States | Post IPO | 1124 | ||
Jul 24, 2026 | United States | Series D | 5844 |
IPOs and Publicly Listed companies in Deep Track Capital's Portfolio
31 of Deep Track Capital's portfolio companies have become public. Latigo Biotherapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Aug 2026 at marketcap of $1.14B and Attovia got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $731M.Here are Deep Track Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 07, 2026 | Jan 28, 2025 | Series B | 5736 | |
Aug 05, 2026 | Apr 15, 2025 | Series C | 1423 | |
Aug 04, 2026 | Sep 09, 2021 | Series B | 5466 | |
May 01, 2026 | Feb 21, 2023 | Series B | 9954 | |
Jan 31, 2025 | Dec 04, 2024 | Series D | 2898 |
Acquired companies in Deep Track Capital's Portfolio
11 companies from Deep Track Capital's portfolio have been acquired. The most recent acquisition was Apogee Therapeutics in Jun 2026 by AbbVie for $*****.Here are Deep Track Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 22, 2026 | Dec 07, 2022 | Series B | 3896 | |
Apr 07, 2026 | Mar 14, 2024 | Series B | 3803 | |
Jan 20, 2026 | Dec 23, 2024 | Post IPO | 9964 | |
Nov 17, 2025 | Aug 12, 2024 | Series B | 5426 | |
Sep 22, 2025 | Nov 12, 2024 | Series B | 8346 |
Team profile of Deep Track Capital
Deep Track Capital has a team of 15 members including 7 Partners located in United States. Deep Track Capital's team does not sit on the board of any company as of now.Here is a list of top team members in Deep Track Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Greenwich | - | ||
Partner | Greenwich | - | - | |
Partner | New York City | - | ||
Partner | Greenwich | - | - | |
Partner | Greenwich | - | - | |
Partner | New York City | - | - | |
Partner | Greenwich | - | - |
Co-investors of Deep Track Capital
Over the past 5 years, 509 investors have co-invested in Deep Track Capital's portfolio companies. This includes funds and angels.
- Invested before Deep Track Capital: RA Capital Management, Orbimed and 262 others have invested in rounds before Deep Track Capital. There are 15 companies where RA Capital Management has invested before Deep Track Capital and 8 companies where Orbimed has invested before Deep Track Capital.
- Top Co-investors of Deep Track Capital: 173 investors entered a company along with Deep Track Capital. These include investors like RA Capital Management (13 companies).
- Invested after Deep Track Capital: A total of 72 investors have invested in Deep Track Capital's portfolio after their investments. Top Investors include Janus Henderson Investors (6 companies), RA Capital Management (3 companies) and TCG Crossover (2 companies).
Recent News related to Deep Track Capital
•
Superluminal Medicines Secures $60 Million for Rare Obesity Therapy DevelopmentPharmaceutical Business Review•Sep 04, 2026•Deep Track Capital, Insight Partners, Nvidia, Cooley and 9 others
•
Draig Therapeutics Secures $65 Million Series B Funding to Advance Brain Drug DevelopmentBioPharmaDive•Jul 14, 2026•Draigtherapeutics, Deep Track Capital, Marshall Wace, Janus Henderson Investors and 1 other
•
Leads Biolabs Partner Oblenio Bio Secures $62 Million Series B Financing for Autoimmune Disease Drug LBL-051GlobeNewswire•Jun 25, 2026•Nanjing Wei Li Zhi Bo Biotechnology, Pfizer, Aditum Bio, Deep Track Capital and 4 others
•
Triveni Bio raises $65M ahead of upcoming readouts on eczema drugsEndpoints•Jun 17, 2026•Triveni Bio, Deep Track Capital, Janus Henderson Investors, Ascenta Capital
•
Terremoto Biosciences Raises $108M in Series C FundingFinSMEs•Apr 15, 2026•Terremoto, RA Capital Management, Deep Track Capital, Cormorant-asset and 4 others
•
Ambrosia Biosciences Announces $100 Million Series BMassinvestor•Apr 06, 2026•Ambrosia Biosciences, Blue Owl, Deep Track Capital
•
Colorado biotech Ambrosia lands $100M for oral GLP-1Endpoints•Mar 31, 2026•Ambrosia Biosciences, Blue Owl, Deep Track Capital, Samsara BioCapital and 8 others
•
ProMIS Neurosciences Announces Up to $175 Million Private PlacementGlobeNewswire•Jan 30, 2026•ProMIS Neurosciences, Deep Track Capital, Great Point Partners
•
Diagonal Therapeutics Announces $125 Million Series B FinancingBenzinga•Jan 08, 2026•Diagonal Therapeutics, Sanofi Ventures, Janus Henderson Investors, RV Invest and 13 others
•
Deep Track Capital Invests in Hemab Therapeutics’ $157 Million Series C FinancingGlobal Legal Chronicle•Nov 21, 2025•Hemab, Deep Track Capital
